Short Interest in Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) Decreases By 62.8%

Coeptis Therapeutics Holdings, Inc. (NASDAQ:COEP) was the recipient of a large decline in short interest in the month of January. As of January 15th, there was short interest totalling 150,700 shares, a decline of 62.8% from the December 31st total of 405,200 shares. Currently, 10.2% of the company’s shares are sold short. Based on an average daily volume of 325,900 shares, the short-interest ratio is currently 0.5 days.

Coeptis Therapeutics Trading Down 13.0 %

Shares of COEP traded down $1.67 during trading hours on Tuesday, hitting $11.21. 128,542 shares of the stock were exchanged, compared to its average volume of 287,652. Coeptis Therapeutics has a fifty-two week low of $2.31 and a fifty-two week high of $13.60. The business has a 50-day moving average of $5.53 and a 200-day moving average of $4.64. The firm has a market capitalization of $26.90 million, a P/E ratio of -1.93 and a beta of -1.04. The company has a debt-to-equity ratio of 0.03, a current ratio of 0.40 and a quick ratio of 0.40.

About Coeptis Therapeutics

Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.